Novartis Ag

Catherine Howsham

Lee Edwards

Emma Budd

Peter Hunt

Nichola Smith

Kamlesh Jagdis Bala

Gurdip Bhalay

Thomas Anthony Hunt

Stephen Paul Collingwood

Katrin Spiegel

Glyn Alan Hughes

Urs Baettig

Graham Charles Bloomfield

Andrew Dunstan

Ian Bruce

Paul Joseph Oakley

Darren Mark LeGrand

Peter Gedeck

Darren Mark Legrand

Roger John Taylor

Brian Cox

Thomas Ullrich

Darren Mark Le Grand

Judy Fox Hayler

Nicola Tufilli

Anett Perlberg

Nicholas James Devereux

Amarylla Horvath

Glyn Hughes

Christian Lindenberg

Lee Edward

Paul Oakley

The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

Pyridine and pyrazine derivative for the treatment of chronic bronchitis

Pyridine and pyrazine derivative for the treatment of CF

A compound of Formula I in free or salt or solvate form, where R, R, R, R, R, R, R, R, R, Rand Rhave the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives

Compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R, R, R, R, R, R, R, R, R, and Rhave the meanings as indicated in the specification, are useful for treating diseases mediated by blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Pyrazine derivatives as ENaC blockers

A compound of Formula I and pharmaceutically acceptable salts and solvates thereof, wherein R, R, R, R, A, B, D and E are all as defined herein. The compounds modulate the activity of CFTR and are useful in the treatment of inflammatory or obstructive airways diseases or mucosal hydration, including, for example cystic fibrosis. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

N-substituted heterocyclyl carboxamides

The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, where R-Rand Y are defined in the description, and its use in the treatment of disorders in which pi3 kinase is implicated.

Pyrazolo [3,4-D] pyrimidine derivatives useful to treat respiratory disorders

The present invention concerns a compound of formula (I) or a salt, suitably a pharmaceutically acceptable salt, or solvate thereof, wherein the groups R, R, Ar', A and Y are defined in the description, to compositions and use of the compounds in the treatment of inflammatory and allergic conditions.

Pyrazine compounds as PI3 kinase inhibitors

This invention relates to a new crystalline form of the succinate salt of the epithelial sodium channel (ENaC) blocker 3-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carbonyl}-benzenesulfonylamino)-propionic acid dipropylcarbamoylmethyl ester, pharmaceutical compositions comprising said crystalline form, uses of said crystalline form and pharmaceutical compositions, and methods for preparing said crystalline form.

Crystalline form

A compound of Formula I in free or salt or solvate form, where R, R, R, R, R, R, R, Rand Rhave the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of airway diseases

Growing community of inventors

Horsham, United Kingdom

Catherine Howsham